SCHEMBL4075710

SCHEMBL4075710

N#Cc1ccc(-c2coc(I)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.46
THRB P10828 1/20 0.46
MYC P01106 5/20 0.44
GAA P10253 1/20 0.44
NOTUM Q6P988 2/20 0.43
HSD11B1 P28845 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MMP3 P08254 1/20 0.38
ALDH1A3 P47895 1/20 0.38
CDC25A P30304 1/20 0.37
CDC25B P30305 1/20 0.37
CDC25C P30307 1/20 0.37
ENPP3 O14638 1/20 0.37
ENPP1 P22413 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10282407 0.79 TP53 (0.67) TP53THRBMYCGAANOTUM
SCHEMBL29045675 0.79 LTA4H (0.51) TP53THRBMYCGAANOTUM
SCHEMBL7454674 0.76 ENPP3 (0.40) GAANPC1RAB9AENPP3ENPP1
SCHEMBL18676204 0.75 ENPP3 (0.45) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1004627 0.75 ENPP3 (0.57) TP53THRBMYCNOTUMGABRA1
SCHEMBL10282408 0.75 TP53 (0.43) TP53THRBMYCGAANOTUM
SCHEMBL2581940 0.75 HSD11B1 (0.52) TP53THRBMYCGAANOTUM
SCHEMBL4575847 0.73 TP53 (0.42) TP53THRBMYCGAANOTUM
SCHEMBL14126158 0.73 NOTUM (0.46) TP53THRBMYCGAANOTUM
SCHEMBL1002380 0.73 GRM5 (0.49) TP53THRBGAANOTUMNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US disclosed
EP-2054410-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS Wyeth (US) 2009-05-06 EP disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US disclosed
WO-2008021331-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS WYETH (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR TP53 762/4885THRB 60/4885MYC 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.